BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9143346)

  • 1. Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle.
    Alcántara AI; Morales M; Delgado E; López-Delgado MI; Clemente F; Luque MA; Malaisse WJ; Valverde I; Villanueva-Peñacarrillo ML
    Arch Biochem Biophys; 1997 May; 341(1):1-7. PubMed ID: 9143346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes.
    Luque MA; González N; Márquez L; Acitores A; Redondo A; Morales M; Valverde I; Villanueva-Peñacarrillo ML
    J Endocrinol; 2002 Jun; 173(3):465-73. PubMed ID: 12065236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle.
    Villanueva-Peñacarrillo ML; Alcántara AI; Clemente F; Delgado E; Valverde I
    Diabetologia; 1994 Nov; 37(11):1163-6. PubMed ID: 7867889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of GLP-1 and exendins action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle.
    Arnés L; González N; Tornero-Esteban P; Sancho V; Acitores A; Valverde I; Delgado E; Villanueva-Peñacarrillo ML
    Int J Mol Med; 2008 Jul; 22(1):127-32. PubMed ID: 18575785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
    Kolligs F; Fehmann HC; Göke R; Göke B
    Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
    Göke R; Fehmann HC; Linn T; Schmidt H; Krause M; Eng J; Göke B
    J Biol Chem; 1993 Sep; 268(26):19650-5. PubMed ID: 8396143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of glucagon-like peptide 1 on the kinetics of glycogen synthase a in hepatocytes from normal and diabetic rats.
    López-Delgado MI; Morales M; Villanueva-Peñacarrillo ML; Malaisse WJ; Valverde I
    Endocrinology; 1998 Jun; 139(6):2811-7. PubMed ID: 9607788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats.
    Barragán JM; Rodríguez RE; Eng J; Blázquez E
    Regul Pept; 1996 Nov; 67(1):63-8. PubMed ID: 8952007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preserved GLP-I effects on glycogen synthase a activity and glucose metabolism in isolated hepatocytes and skeletal muscle from diabetic rats.
    Morales M; López-Delgado MI; Alcántara A; Luque MA; Clemente F; Márquez L; Puente J; Viñambres C; Malaisse WJ; Villanueva-Peñacarrillo ML; Valverde I
    Diabetes; 1997 Aug; 46(8):1264-9. PubMed ID: 9231649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normalizing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states.
    Moreno P; Nuche-Berenguer B; Gutiérrez-Rojas I; Acitores A; Sancho V; Valverde I; González N; Villanueva-Peñacarrillo ML
    J Mol Endocrinol; 2012 Feb; 48(1):37-47. PubMed ID: 22065862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of intracerebroventricular injection of glucagon like peptide-1 and its related peptides on serotonin metabolism and on levels of amino acids in the rat hypothalamus.
    Owji AA; Khoshdel Z; Sanea F; Panjehshahin MR; Shojaee Fard M; Smith DM; Coppock HA; Ghatei MA; Bloom SR
    Brain Res; 2002 Mar; 929(1):70-5. PubMed ID: 11852032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
    Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
    Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect.
    Dhanesha N; Joharapurkar A; Shah G; Dhote V; Kshirsagar S; Bahekar R; Jain M
    Pharmacol Rep; 2012; 64(1):140-9. PubMed ID: 22580530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
    Parkes DG; Pittner R; Jodka C; Smith P; Young A
    Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.
    Perry T; Lahiri DK; Chen D; Zhou J; Shaw KT; Egan JM; Greig NH
    J Pharmacol Exp Ther; 2002 Mar; 300(3):958-66. PubMed ID: 11861804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1.
    Idris I; Patiag D; Gray S; Donnelly R
    Biochem Pharmacol; 2002 Mar; 63(5):993-6. PubMed ID: 11911852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of exendin-4 treatment upon glucose uptake parameters in rat liver and muscle, in normal and type 2 diabetic state.
    Arnés L; Moreno P; Nuche-Berenguer B; Valverde I; Villanueva-Peñacarrillo ML
    Regul Pept; 2009 Feb; 153(1-3):88-92. PubMed ID: 18804493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide 1: a potent glycogenic hormone.
    Valverde I; Morales M; Clemente F; López-Delgado MI; Delgado E; Perea A; Villanueva-Peñacarrillo ML
    FEBS Lett; 1994 Aug; 349(2):313-6. PubMed ID: 8050588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inositolphosphoglycans are possible mediators of the glucagon-like peptide 1 (7-36)amide action in the liver.
    Trapote MA; Clemente F; Galera C; Morales M; Alcántara AI; López-Delgado MI; Villanueva-Peñacarrillo ML; Valverde I
    J Endocrinol Invest; 1996 Feb; 19(2):114-8. PubMed ID: 8778163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor.
    Yang H; Egan JM; Wang Y; Moyes CD; Roth J; Montrose MH; Montrose-Rafizadeh C
    Am J Physiol; 1998 Sep; 275(3):C675-83. PubMed ID: 9730951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.